Insider · CIK 0001977608
Teresa Marie Bitetti
Files at TAK (TAKEDA PHARMACEUTICAL CO LTD), AURA (Aura Biosciences, Inc.). First filing Aug 12, 2026, latest Aug 12, 2026.
In brief
Teresa Marie Bitetti files SEC Form 4 as director and president at TAK (TAKEDA PHARMACEUTICAL CO LTD), and also at AURA (Aura Biosciences, Inc.). Since Aug 12, 2026, Teresa Marie Bitetti has reported 0 open-market buys worth $0 and 1 open-market sell worth $855k, the latest filed on Aug 12, 2026.
A track record needs three past buys with six months of prices behind them; Teresa Marie Bitetti has 0, so none is measured yet.
The newest scored trade: sold $855k of TAK on Aug 10, 2026, filed Aug 12, 2026, scored 63 (notable). In the last 12 months: 0 buys worth $0 and 1 sell worth $855k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TAK: TAKEDA PHARMACEUTICAL CO LTD
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 63Notable | TAKEDA PHARMACEUTICAL CO LTD | $855k 50,012 shares | -17% | +33% from low-7% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 13, 2026 | TAK Takeda Pharmaceutical Company Limited | 54,210 0.04% of outstanding | $908k | Jul 13, 2026 | none |
| Dec 5, 2025 | TAK Takeda Pharmaceutical Company Limited | 87,023 0.07% of outstanding | $1.2M | Dec 5, 2025 | none |
| Jul 9, 2025 | TAK Takeda Pharmaceutical Company Limited | 52,649 0.04% of outstanding | $812k | Jul 9, 2025 | none |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | SOpen-market sale American Depositary Shares | -50,012 | $17.10 | $855k | 252,010 | Aug 12, 2026 |
| Jul 1, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | AGrant or award American Depositary Shares | +43,886 | $0.00 | $0 | 302,022 | Jul 6, 2026 |
| Jun 11, 2026 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 36,000 | Jun 15, 2026 |
| Jun 11, 2026 | AURA Aura Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 15, 2026 |
| Apr 27, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | AGrant or award American Depositary Shares | +64,988 | $0.00 | $0 | 258,136 | Apr 28, 2026 |
| Mar 31, 2025 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +21,000 | $0.00 | $0 | 21,000 | Apr 2, 2025 |
| Mar 31, 2025 | AURA Aura Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +29,000 | $0.00 | $0 | 29,000 | Apr 2, 2025 |
Questions about Teresa Marie Bitetti
Answered from the filings on this page, as of the latest one.
Is Teresa Marie Bitetti buying or selling?
In the last 12 months Teresa Marie Bitetti reported 0 open-market buys worth $0 and 1 open-market sell worth $855k on SEC Form 4; the latest was sold $855k of TAK on Aug 10, 2026. Grants, option exercises and tax withholding are not counted.
How did Teresa Marie Bitetti's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Teresa Marie Bitetti has 0.
Where does Teresa Marie Bitetti file Form 4?
Teresa Marie Bitetti has filed Form 4 at TAK (TAKEDA PHARMACEUTICAL CO LTD) as President, OBU; AURA (Aura Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.